Immunoglobulin A Nephropathy

Nephrology
6
Pipeline Programs
3
Companies
5
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
1
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Travere Therapeutics
FILSPARIApproved
sparsentan
Travere Therapeutics
Endothelin Receptor Antagonist [EPC]oral2023

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Travere Therapeutics
3 programs
2
1
1
sparsentanPhase 31 trial
SparsentanPhase 21 trial
SparsentanPhase 21 trial
Active Trials
NCT05856760Completed48Est. Oct 2024
NCT04663204Active Not RecruitingEst. Mar 2025
NCT03762850Active Not Recruiting406Est. Jul 2026
VP
1 program
1
PovetaciceptPhase 31 trial
Active Trials
NCT06564142Active Not RecruitingEst. Jan 2028
Takeda
TakedaTOKYO, Japan
1 program
1
SM101Phase 21 trial
Active Trials
NCT02605525Withdrawn0Est. Nov 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Vertex PharmaceuticalsPovetacicept
Travere Therapeuticssparsentan
Travere TherapeuticsSparsentan
Travere TherapeuticsSparsentan
TakedaSM101

Clinical Trials (5)

Total enrollment: 454 patients across 5 trials

NCT06564142Vertex PharmaceuticalsPovetacicept

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

Start: Aug 2024Est. completion: Jan 2028
Phase 3Active Not Recruiting
NCT03762850Travere Therapeuticssparsentan

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

Start: Dec 2018Est. completion: Jul 2026406 patients
Phase 3Active Not Recruiting
NCT05856760Travere TherapeuticsSparsentan

A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

Start: May 2023Est. completion: Oct 202448 patients
Phase 2Completed
NCT04663204Travere TherapeuticsSparsentan

A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy

Start: Dec 2020Est. completion: Mar 2025
Phase 2Active Not Recruiting
NCT02605525TakedaSM101

Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy

Start: Dec 2015Est. completion: Nov 20160
Phase 2Withdrawn

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
1w ago

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Specialty Account Manager, Nephrology- South Houston, Texas

Amgen
Texas - Houston, US
1w ago
$155K - $184K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)